TYK2 and acute lymphoblastic leukemia: In accordance with this, Tavakoli Shirazi P et al. (2021) demonstrate that JAKi withdrawal could restore the sensitivity to JAK inhibition in a preclinical model of TYK2 deregulated B-ALL [8].